Cargando…

Glycosphingolipid Modification: Structural Diversity, Functional and Mechanistic Integration of Diabetes

Glycosphingolipids (GSLs) are present in all mammalian cell plasma membranes and intracellular membrane structures. They are especially concentrated in plasma membrane lipid domains that are specialized for cell signaling. Plasma membranes have typical structures called rafts and caveola domain stru...

Descripción completa

Detalles Bibliográficos
Autor principal: Yamashita, Tadashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Diabetes Association 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3178690/
https://www.ncbi.nlm.nih.gov/pubmed/21977449
http://dx.doi.org/10.4093/dmj.2011.35.4.309
_version_ 1782212426107715584
author Yamashita, Tadashi
author_facet Yamashita, Tadashi
author_sort Yamashita, Tadashi
collection PubMed
description Glycosphingolipids (GSLs) are present in all mammalian cell plasma membranes and intracellular membrane structures. They are especially concentrated in plasma membrane lipid domains that are specialized for cell signaling. Plasma membranes have typical structures called rafts and caveola domain structures, with large amounts of sphingolipids, cholesterol, and sphingomyelin. GSLs are usually observed in many organs ubiquitously. However, GSLs, including over 400 derivatives, participate in diverse cellular functions. Several studies indicate that GSLs might have an effect on signal transduction related to insulin receptors and epidermal growth factor receptors. GSLs may modulate immune responses by transmitting signals from the exterior to the interior of the cell. Guillain-Barré syndrome is one of the autoimmune disorders characterized by symmetrical weakness in the muscles of the legs. The targets of the immune response are thought to be gangliosides, which are one group of GSLs. Other GSLs may serve as second messengers in several signaling pathways that are important to cell survival or programmed cell death. In the search for clear evidence that GSLs may play critical roles in various biological functions, many researchers have made genetically engineered mice. Before the era of gene manipulation, spontaneous animal models or chemical-induced disease models were used.
format Online
Article
Text
id pubmed-3178690
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Korean Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-31786902011-10-04 Glycosphingolipid Modification: Structural Diversity, Functional and Mechanistic Integration of Diabetes Yamashita, Tadashi Diabetes Metab J Review Glycosphingolipids (GSLs) are present in all mammalian cell plasma membranes and intracellular membrane structures. They are especially concentrated in plasma membrane lipid domains that are specialized for cell signaling. Plasma membranes have typical structures called rafts and caveola domain structures, with large amounts of sphingolipids, cholesterol, and sphingomyelin. GSLs are usually observed in many organs ubiquitously. However, GSLs, including over 400 derivatives, participate in diverse cellular functions. Several studies indicate that GSLs might have an effect on signal transduction related to insulin receptors and epidermal growth factor receptors. GSLs may modulate immune responses by transmitting signals from the exterior to the interior of the cell. Guillain-Barré syndrome is one of the autoimmune disorders characterized by symmetrical weakness in the muscles of the legs. The targets of the immune response are thought to be gangliosides, which are one group of GSLs. Other GSLs may serve as second messengers in several signaling pathways that are important to cell survival or programmed cell death. In the search for clear evidence that GSLs may play critical roles in various biological functions, many researchers have made genetically engineered mice. Before the era of gene manipulation, spontaneous animal models or chemical-induced disease models were used. Korean Diabetes Association 2011-08 2011-08-31 /pmc/articles/PMC3178690/ /pubmed/21977449 http://dx.doi.org/10.4093/dmj.2011.35.4.309 Text en Copyright © 2011 Korean Diabetes Association http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Yamashita, Tadashi
Glycosphingolipid Modification: Structural Diversity, Functional and Mechanistic Integration of Diabetes
title Glycosphingolipid Modification: Structural Diversity, Functional and Mechanistic Integration of Diabetes
title_full Glycosphingolipid Modification: Structural Diversity, Functional and Mechanistic Integration of Diabetes
title_fullStr Glycosphingolipid Modification: Structural Diversity, Functional and Mechanistic Integration of Diabetes
title_full_unstemmed Glycosphingolipid Modification: Structural Diversity, Functional and Mechanistic Integration of Diabetes
title_short Glycosphingolipid Modification: Structural Diversity, Functional and Mechanistic Integration of Diabetes
title_sort glycosphingolipid modification: structural diversity, functional and mechanistic integration of diabetes
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3178690/
https://www.ncbi.nlm.nih.gov/pubmed/21977449
http://dx.doi.org/10.4093/dmj.2011.35.4.309
work_keys_str_mv AT yamashitatadashi glycosphingolipidmodificationstructuraldiversityfunctionalandmechanisticintegrationofdiabetes